Safety and Efficacy of Oral Artesunate for Pre-cervical Cancer

Inclusion Criteria: * Aged 18 or over * Histologically proven HPV positive cervical CIN2/3 * WHO performance status 0-2 * Adequate full blood count: * White Cell Count (WCC) \>3.0 x 109 /l; * Platelets \>100 x 109/l; * Haemoglobin (Hb) \>80g/L * Adequate renal function: * Glomerular Filtration Rate \>30ml/min * Adequate hepatobiliary function: * Total bilirubin \< 3 x Upper limit normal * Female participants of child bearing potential must have a negative pregnancy test \< 72 hours prior to initiating study intervention and agree to avoid pregnancy using adequate, medically approved contraceptive precautions for up to 6 weeks after the last dose of study treatment intervention * Patient able and willing to provide written, informed consent for the study Exclusion Criteria: * • Contraindication to the use of artesunate due to hypersensitivity * Pregnancy or lactation * Weight \< 52 kg * History of previous CIN * Immunocompromised patients